Luxendo intends to use funds to drive the uptake of its Single Plane Illumination Microscopes internationally
Heidelberg, Germany, 12 January 2017 - Luxendo, a privately held start-up spun out of the European Molecular Biology Laboratory and developing its proprietary Single Plane Illumination Microscopy (SPIM) technology for biomedical research, announces today that the total capital raised in the Series A is €8 million. This follows a funding extension which was led by LSP, Munich, EMBL Ventures, Heidelberg and EMBL Enterprise Management Technology Transfer GmbH (EMBLEM).
Luxendo will use these funds to drive the international sales of its Single Plane Illumination Microscopes by expanding its international sales and marketing team. Luxendo also intends to invest in the production capacity needed to support its growth.
Luxendo launched two different microscopes Mu-VI- and In-Vi- SPIM in 2016. Both microscopes are based on the SPIM technology. This technology allows scientists to observe living organisms for extended periods of time without them being adversely impacted by photo-toxicity. Luxendo’s microscopes are able to avoid sample photo-toxicity by just illuminating sequentially a stack of small slices of the organism that is actively being viewed.
A version of the company's press release can be found here.
About Luxendo
Luxendo is the most recent spin-off company from the European Molecular Biology Laboratory (EMBL). The Company develops and internationally markets its Single Plane Illumination Microscopes which are based on its proprietary Single Plane Illumination Microscopy (SPIM) technology.
The Company currently markets the MuVI- and InVi- SPIM microscopes.
The MuVi-SPIM microscope allows fast 3D imaging of living objects such as spheroids and whole specimens for extended periods of time, and without the need of sample rotation.
The InVi-SPIM microscope allows extremely gentle sample handling. It is designed for fast 3D imaging of living objects such as cell cultures and developing embryonic samples.
Luxendo was founded in October 2015. The Company is headquartered in Heidelberg, Germany, and is funded by EMBL Ventures and LSP. To-date it has raised a total of €8 million.
For more information, please visit www.luxendo.eu
About LSP
LSP is a leading independent European investment firm, providing financing for private and public life-science companies. Since the late 1980s, LSP’s management has invested in a large number of highly innovative enterprises, many of which have grown to become leaders of the global life-science industry. With over $1 billion of investment capital raised to date and offices in Amsterdam, Munich and Boston, LSP is one of Europe’s largest and most experienced specialist life-science investors.
For more information, please visit www.lspvc.com
About EMBL Enterprise Management Technology Transfer GmbH
EMBLEM, established in 1999, identifies, protects and commercializes the intellectual property developed in the EMBL world, from EMBL alumni and from non-EMBL third parties. EMBLEM facilitates and accelerates the transfer of innovative technology from basic research to industry by working closely with industrial partners spanning the biotech, IT and mechanical/electrical engineering markets.
For more information, please visit www.embl-em.de
About EMBL Ventures GmbH
EMBL Ventures invests throughout Europe in life-science companies with the aim to create significant commercial opportunities based on new therapeutic treatment modalities, next generation enabling technology platforms or innovations in the diagnostics and device area. EMBL Ventures manages over €120m on behalf of major European institutional and private investors and typically invests €3 to 8m as lead or co-lead investor.
For more information, please visit embl-ventures.com
About The European Molecular Biology Laboratory
The European Molecular Biology Laboratory (EMBL) is a Europe’s flagship laboratory for the life sciences, with more than 80 independent groups covering the spectrum of structural, molecular, cellular and developmental biology. Founded in 1974, EMBL is an inter-governmental organization funded by public research money from its more than 20 member states. The Institute with over 1,600 employees operates across five sites: the main laboratory in Heidelberg, and outstations in Grenoble, Hamburg, Hinxton near Cambridge (the European Bioinformatics Institute EBI), and Monterotondo near Rome.
For more information, please visit www.embl.de
« back to overview